CAH

Spruce Biosciences Announces Poster Presentations at the 2024 Annual Meeting of the Endocrine Society

Retrieved on: 
onsdag, maj 22, 2024
Biotechnology, Pharmaceutical, Health, ENDO, Congenital adrenal hyperplasia, Polycystic ovary syndrome, PCOS, Feinberg School of Medicine, Endocrine Society, Risk, Treatment, Diabetes, Associate professor, CAH, Division, Associate, Abstract, Mortality, Johns Hopkins University, Metabolism, Molecular medicine, Pharmaceutical industry

Spruce Biosciences, Inc .

Key Points: 
  • Spruce Biosciences, Inc .
  • (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that three submitted abstracts were accepted for the 106th Annual Meeting of the Endocrine Society (ENDO 2024) taking place June 1-4, 2024, in Boston.
  • In a poster presentation, the company will present final results from its Phase 2 POWER study of tildacerfont for the treatment of polycystic ovary syndrome (PCOS).
  • Access more information about ENDO 2024 here .

Spruce Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Retrieved on: 
måndag, maj 13, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Congenital adrenal hyperplasia, Androstenedione, Patient, PCOS, Polycystic ovary syndrome, Hyperandrogenism, ACTH, Food, Annual general meeting, PES, Clinical trial, FDA, Conference, CAH, Endocrine system, GC, Adrenocorticotropic hormone, Research and development, Cash, Administration, Pharmaceutical industry

(Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the first quarter ended March 31, 2024 and provided corporate updates.

Key Points: 
  • (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the first quarter ended March 31, 2024 and provided corporate updates.
  • ET and in a fireside chat at the RBC Capital Markets Global Healthcare Conference on May 15, 2024 at 8:30 a.m.
  • Operating expenses include non-cash stock-based compensation expenses of $1.6 million and $1.1 million for the three months ended March 31, 2024 and 2023, respectively.
  • Net Loss: Net loss for the three months ended March 31, 2024 was $11.6 million, compared to $12.8 million for the same period in 2023.

Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024

Retrieved on: 
torsdag, maj 9, 2024
Disorder, Common, Risk, GC, Overweight, Trial of the century, Adrenocorticotropic hormone, Hyperlipidemia, Associate, Deficit spending, Hydrocortisone, Neurocrine Biosciences, White matter, Food, Oklahoma State University–Stillwater, Cognition, Psychology, Testosterone, Male, Literature, Brain, DSM-IV codes, A4, SAN, GCS, CAH, Acne, Safety, Glucocorticoid, Research, Depression, Congenital adrenal hyperplasia, Osteopenia, Anxiety, Division, Hirsutism, Androstenedione, Psychiatry, Psychosis, Hypertension, Metabolism, Poster, Pharmaceutical industry

The CAHtalyst Adult study baseline data demonstrate the potential long-term consequences of current CAH treatments, with many patients in young adulthood experiencing disorders found more commonly in people decades older, including osteopenia, hypertension and hyperlipidemia.

Key Points: 
  • The CAHtalyst Adult study baseline data demonstrate the potential long-term consequences of current CAH treatments, with many patients in young adulthood experiencing disorders found more commonly in people decades older, including osteopenia, hypertension and hyperlipidemia.
  • These new data were presented at oral presentations and poster sessions at the American Association of Clinical Endocrinology 2024 Annual Meeting in New Orleans.
  • Despite supraphysiologic GC dosing, levels of adrenocorticotropic hormone, 17-hydroxyprogesterone and androstenedione (A4) were elevated at baseline, with levels of testosterone (females) and A4/testosterone (males) also elevated.
  • The data from both studies supported two New Drug Applications submitted to the U.S. Food and Drug Administration in April 2024.

Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
torsdag, maj 9, 2024
ENDO, Defecation, FDA, Holocene, Investment, CAH, Safety, NDA, Pharmacokinetics, Food, Carcinoid syndrome, Research, Acromegaly, Conference, Webcast, Congenital adrenal hyperplasia, Endocrine system, Therapy, Patient, Cushing's disease, SAN, End, Pharmaceutical industry

SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today reported financial results for the first quarter ended March 31, 2024.

Key Points: 
  • ET Today
    SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today reported financial results for the first quarter ended March 31, 2024.
  • “Building on the positive momentum from the first PATHFNDR readout in 2023, Crinetics began 2024 with continued strong performance.
  • We plan to report initial results from a subset of patients from these trials in the second quarter,” continued Dr. Struthers.
  • In March, Crinetics reported positive topline results from its placebo-controlled Phase 3 study of paltusotine in non-pharmacologically treated participants with acromegaly.

Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024

Retrieved on: 
onsdag, maj 8, 2024
ENDO, Molecule, Science, Efficacy, Hyperplasia, ACTH, Safety, CAH, ASD, Policy, Abstract, Serum, Innovation, Lanreotide, Octreotide, Barrow Neurological Institute, Endocrine Society, Single Center, Congenital adrenal hyperplasia, A4, Endocrine system, Pharmaceutical industry

SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced five abstracts from its clinical development programs, including four late-breaking abstracts, will be presented at the Endocrine Society’s annual meeting, ENDO 2024, taking place June 1-4, 2024 in Boston, Massachusetts.

Key Points: 
  • One presentation will showcase initial safety and key biomarker efficacy findings in CAH, including rapid and profound reductions in androstenedione (A4) and 17-hydroxyprogesterone levels in participants, from the Phase 2 open label TouCAHn study.
  • A second presentation includes data from a Phase 1b/2a open-label single center study of atumelnant in ACTH-dependent Cushing’s syndrome and will feature the first evidence of rapid and sustained cortisol reductions in participants.
  • Crinetics will also have a poster presentation with data from the Phase 3 PATHFNDR-2 study evaluating paltusotine in acromegaly patients who were medically untreated.
  • Data from the PATHFNDR program will be featured in a Science and Innovation Theater led by Dr. Kevin C.J.

Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024

Retrieved on: 
tisdag, maj 7, 2024
Safety, Patient, Neurocrine Biosciences, CAH, Abstract, Hydrocortisone, Congenital adrenal hyperplasia, ECE, Adrenal crisis, Treatment, Adrenocorticotropic hormone, Capsule, SAN, Incidence, Pharmaceutical industry

SAN DIEGO, May 7, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present key information from its neuroendocrinology pipeline, including baseline characteristics data from its CAHtalyst™ Program of crinecerfont in congenital adrenal hyperplasia (CAH), as well as data from its modified-release hydrocortisone studies in primary adrenal insufficiency and CAH, at the European Congress of Endocrinology 2024 meeting in Sweden, May 11–14.

Key Points: 
  • SAN DIEGO, May 7, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present key information from its neuroendocrinology pipeline, including baseline characteristics data from its CAHtalyst™ Program of crinecerfont in congenital adrenal hyperplasia (CAH), as well as data from its modified-release hydrocortisone studies in primary adrenal insufficiency and CAH, at the European Congress of Endocrinology 2024 meeting in Sweden, May 11–14.
  • Neurocrine Biosciences will be presenting several abstracts and posters at ECE 2024, including:
    Baseline Characteristics of Children and Adolescents with Classic Congenital Adrenal Hyperplasia Enrolled in CAHtalyst Pediatric, a Phase 3 Study of Crinecerfont, a Corticotropin-Releasing Factor Type 1 Receptor Antagonist
    Baseline Characteristics of Adults with Classic Congenital Adrenal Hyperplasia Enrolled in CAHtalyst Adult, a Phase 3 Study of Crinecerfont, a Corticotropin-Releasing Factor Type 1 Receptor Antagonist
    CHAMPAIN study: Initial Results from a Phase II Study of Efficacy, Safety and Tolerability of Modified-Release Hydrocortisones: Chronocort® (Efmody®) versus Plenadren, in Primary Adrenal Insufficiency,
    Biochemical Control with Dose Reduction in Chronic Glucocorticoid Therapy over 4 Years: A Phase III Extension Study of Chronocort (Efmody®) in the Treatment of Congenital Adrenal Hyperplasia (CAH)
    Incidence of Adrenal Crisis in Congenital Adrena Hyperplasia (CAH) Patients During a Prospective Monitored Long-Term study of Modified-Release Hydrocortisone (MRHC) Capsules, (Efmody)

Neurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024

Retrieved on: 
fredag, maj 3, 2024
Weill Cornell Medical Center, Hyperplasia, Weill Cornell Medicine, Patient, Neurocrine Biosciences, Clinical Pediatrics, CAH, Safety, GC, Androstenedione, Food, Male, Congenital adrenal hyperplasia, Observation, Obesity, Disease, D.O, Hirsutism, Diagnosis, Poster, Associate, Adrenocorticotropic hormone, Natural history, SAN, Pharmaceutical industry

SAN DIEGO, May 3, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today presented the CAHtalyst™ Pediatric Phase 3 clinical study baseline characteristics data for children and adolescents with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency enrolled in the study, along with CAHtalog™ Registry data assessing glucocorticoid treatment patterns in pediatric and adult patients with CAH.

Key Points: 
  • SAN DIEGO, May 3, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today presented the CAHtalyst™ Pediatric Phase 3 clinical study baseline characteristics data for children and adolescents with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency enrolled in the study, along with CAHtalog™ Registry data assessing glucocorticoid treatment patterns in pediatric and adult patients with CAH.
  • These new data were presented at the Pediatric Endocrine Society 2024 Annual Meeting in Chicago.
  • Baseline characteristics of the subjects who enrolled in the CAHtalyst Pediatric Phase 3 study were presented (Poster# 56).
  • Neurocrine Biosciences also presented glucocorticoid treatment patterns from a recent cohort of pediatric and adult patients participating in the CAHtalog Registry (Poster# 51).

Spruce Biosciences Announces Additional Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting

Retrieved on: 
tisdag, april 30, 2024
Biotechnology, General Health, Pharmaceutical, Health, CAH, PES, Poster, Congenital adrenal hyperplasia, Annual general meeting, Pharmaceutical industry

Spruce Biosciences, Inc .

Key Points: 
  • Spruce Biosciences, Inc .
  • (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that an accepted abstract highlighting baseline characteristics from the company’s CAHptain Phase 2 study evaluating tildacerfont in children and adolescents with congenital adrenal hyperplasia (CAH) will be presented at the Pediatric Endocrine Society (PES) 2024 Annual Meeting taking place May 2-5, 2024, in Chicago, IL.
  • In addition, a submitted abstract highlighting baseline characteristics from Spruce’s CAHmelia program evaluating tildacerfont in adult CAH, as an illustration of outcomes of current pediatric CAH disease management, was accepted for poster presentation at the PES conference.
  • PES 2024 Poster Presentation Details:
    Presenter: Mimi S. Kim, M.D., Co-Director, Congenital Adrenal Hyperplasia Comprehensive Care Clinic, Children’s Hospital Los Angeles
    Title: Baseline Characteristics of Two Randomized, Placebo-controlled Trials with Tildacerfont in Adults (CAHmelia Studies) Highlight Unmet Medical Need in Pediatric Congenital Adrenal Hyperplasia
    The poster presentations will be available on the company’s website beginning May 3, 2024 at 12:15 p.m. CT. Access more information about PES 2024 here .

Spruce Biosciences Announces Upcoming Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting

Retrieved on: 
måndag, april 22, 2024
Biotechnology, General Health, Pharmaceutical, Health, Congenital adrenal hyperplasia, Poster, Annual general meeting, PES, CAH

Spruce Biosciences, Inc .

Key Points: 
  • Spruce Biosciences, Inc .
  • (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that a submitted abstract was accepted for poster presentation at the Pediatric Endocrine Society (PES) 2024 Annual Meeting taking place May 2-5, 2024, in Chicago, IL.
  • In the poster presentation, Paul Thornton, M.B.B.S., will highlight baseline characteristics from Spruce’s CAHmelia program evaluating tildacerfont in adult congenital adrenal hyperplasia (CAH), as an illustration of outcomes of current pediatric CAH disease management.
  • Title: Baseline Characteristics of Two Randomized, Placebo-controlled Trials with Tildacerfont in Adults (CAHmelia Studies) Highlight Unmet Medical Need in Pediatric Congenital Adrenal Hyperplasia
    The poster will be available on the company’s website beginning May 3, 2024 at 12:15 p.m. CT. Access more information about PES 2024 here .

Hunting PLC ("Hunting" or "the Company" or "the Group") Celebrating 150 Years of Excellence

Retrieved on: 
måndag, april 15, 2024
Other Energy, Utilities, Oil, Gas, Other Manufacturing, Energy, Machine Tools, Metalworking & Metallurgy, Engineering, Manufacturing, Petro, Innova, Titan, Hunting plc, Titan Corporation, WL, CAH, Investment, Lubricant, Artificial intelligence, Transport, History, Growth, DNA, Family, HTG, Acquisition, Electronics, INSYS, PLC, World war, Renewable energy

The entrepreneurial ethos instilled by our founder, Charles Samuel Hunting, in 1874 remains deeply embedded within our organisational DNA.

Key Points: 
  • The entrepreneurial ethos instilled by our founder, Charles Samuel Hunting, in 1874 remains deeply embedded within our organisational DNA.
  • Charles Samuel Hunting ventured into the oil industry during the 1890s, building upon the foundation of a prosperous ship-owning enterprise established by his father, Charles Hunting.
  • Originally, the Hunting interests were privately owned and operated as three distinct quoted companies: Hunting Oilfield Services, Hunting Engineering, and Hunting Energy Services.
  • However, in 1989, Clive Hunting led the merger of these entities into the unified organisation known today as Hunting PLC.